Biocryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals develops and sells medicines for hereditary angioedema and other rare diseases. It last closed at $7.50 on Nov 17, up 0.67% on the day. The average 12-month price target from 4 analysts is $14.25 (+90.0% from the last close), with a high of $17.00 and a low of $11.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From BCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on BCRX in the past 90 days. The average target is $14.25, with a high of $17.00 and a low of $11.00, compared with the last close of $7.50.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Wedbush | Target lowered | Buy | $20 → $17 |
| Sep 30 | JP Morgan | Target raised | Hold | $12 → $13 |
| Sep 10 | RBC Capital | Downgrade | Hold | $14 → $11 |
| Sep 8 | Needham | Reiterated | Buy | $16 |
| Aug 6 | Wedbush | Maintained | Buy | $20 |
Technical Analysis
The stock is 5% below its 20 day and 9% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $7.45, and the nearest resistance the Pivot R1 at $7.57.
| RSI (14) | 39.36 | Weak, oversold below 30 | Neutral |
| MACD | -0.21 | Below its signal line | Bearish |
| Stochastic | 10.5 | Near the bottom of its range | Oversold |
| ADX (14) | 15.2 | No clear trend | |
| Williams %R | -88.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -95.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −12.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.33 | Typical daily range, 4.4% of price |
| RSI (14) | 41.49 | Middle of its range | Neutral |
| MACD | -0.32 | Below its signal line | Bearish |
| Stochastic | 7.4 | Near the bottom of its range | Oversold |
| ADX (14) | 15.1 | No clear trend | |
| Williams %R | -94.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -113.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −7.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.87 | Typical daily range, 11.6% of price |
What happened before
See how BCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in BCRX in the last 90 days.
BCRX Institutional Ownership
Full report →- ●149 buying vs 165 selling
- ▼Held by funds -7.8 pts
- ▲Funds holding +15
- ▼Superinvestors: 2 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 334 | 319 | +4.7% |
| In funds' top 10 | 1 | 0 | – |
| Held by funds | 94.8% | 102.5% | −7.8 pts |
| New / increased | 52 / 97 | 53 / 133 | −19.9% |
| Reduced / sold out | 127 / 38 | 85 / 38 | +34.1% |
| Put/call ratio | 0.00 | 0.01 | −90.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCRX is in one of them and how their past BCRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BCRX in an article yet. Here's the latest on the wider market.
BCRX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jul 10, 2026 | Sep 4, 2026 | 56 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Nov 13, 2025 | Dec 15, 2025 | 32 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Oct 16, 2023 | Nov 11, 2023 | 26 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Sep 15, 2023 | Oct 15, 2023 | 30 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Biocryst Pharmaceuticals
BioCryst Pharmaceuticals is a biotechnology company based in Durham, North Carolina. It develops and sells medicines for hereditary angioedema and other rare diseases. Its main product, ORLADEYO, is an oral medicine taken once daily to prevent attacks of hereditary angioedema, and it is approved in the United States and several other markets. The company also has RAPIVAB, an intravenous treatment for influenza, approved in several countries. Its customers include patients with these conditions, along with the healthcare providers and insurers who support their care.
- Headquarters
- Durham, NC
- Founded
- 1986
- Website
- biocryst.com ↗






